Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients

International Journal of Cardiology

Volumn 166, Issue 2, 2013, Pages 431-439

  Ribeiro, Rodrigo Antonini ^a,b   Ziegelmann, Patricia Klarmann ^a,b   Duncan, Bruce Bartholow ^a,b   Stella, Steffan Frosi ^a,b   Da Costa Vieira, José Luiz ^c   Restelatto, Luciane Maria Fabian ^d   Moriguchi, Emílio Hideyuki ^a   Polanczyk, Carisi Anne ^a,b,d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b CNPq   (Brazil)

^c INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cardiovascular events; Mixed treatment comparisons; Statins; Systematic reviews

Indexed keywords

ATORVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CREATINE KINASE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; META ANALYSIS; MIXED TREATMENT COMPARISON; MORTALITY; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TYPES OF STUDY;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84878012897     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.10.128     Document Type: Article

References (73)

1. S. Ward, M. Lloyd Jones, and A. Pandor A systematic review and economic evaluation of statins for the prevention of coronary events Health Technol Assess 11 2007 1 160 [iii-iv]
2. J.R. Kizer, C. Madias, and B. Wilner Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy Am J Cardiol 105 2010 1289 1296
3. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
4. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
5. E.J. Mills, C. O'Regan, and O. Eyawo Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of > 40 000 patients Eur Heart J 32 2011 1409 1415
6. K.A. Robinson, and K. Dickersin Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed Int J Epidemiol 31 2002 150 153
7. E.J. Mills, P. Wu, and G. Chong Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials QJM 104 2011 109 124
8. T. Nakagawa, T. Kobayashi, and N. Awata Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study Int J Cardiol 97 2004 107 114
9. H. Nakamura, K. Arakawa, and H. Itakura Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 2006 1155 1163
10. J.P.T. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions 2009 Available from: http://www.cochrane-handbook.org 2009
11. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
12. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
13. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
14. G. Lu, and A.E. Ades Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 2004 3105 3124
15. S. Dias, N.J. Welton, D.M. Caldwell, and A.E. Ades Checking consistency in mixed treatment comparison meta-analysis Stat Med 29 2010 932 944
16. A.G. Olsson, M. Eriksson, and O. Johnson A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study Clin Ther 25 2003 119 138
17. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
18. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia Diabetes Care 24 2001 1335 1341
19. T.R. Pedersen, O. Faergeman, and J.J. Kastelein High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
20. E.R. Mohler III, W.R. Hiatt, and M.A. Creager Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease Circulation 108 2003 1481 1486
21. A. Schmermund, S. Achenbach, and T. Budde Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial Circulation 3 2006 Available from: http://www.mrw. interscience.wiley.com/cochrane/clcentral/articles/293/CN-00554293/frame.html [serial on the Internet]
22. J. Armitage, L. Bowman, and K. Wallendszus Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
23. J. LaRosa, S. Grundy, and D. Waters Treating to New Targets (TNT) investigators intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
24. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
25. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 9 2004 Available from: http://www.mrw. interscience.wiley.com/cochrane/clcentral/articles/164/CN-00468164/frame.html [serial on the Internet]
26. P. Deedwania, P.H. Stone, and C.N. Bairey Merz Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE) Circulation 6 2007 Available from: http://www.mrw.interscience.wiley. com/cochrane/clcentral/articles/235/CN-00578235/frame.html [serial on the Internet]
27. M.J. Koren, and D.B. Hunninghake Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study J Am Coll Cardiol 44 2004 1772 1779
28. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
29. D.H. Blankenhorn, S.P. Azen, and D.M. Kramsch Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) Ann Intern Med 119 1993 969 976
30. P. Amarenco, J. Bogousslavsky, and A. Callahan III High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
31. C.M. Ballantyne, A.G. Olsson, T.J. Cook, M.F. Mercuri, T.R. Pedersen, and J. Kjekshus Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
32. C.D. Furberg, H.P. Adams, and W.B. Applegate Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group Circulation 4 1994 Available from: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/780/CN- 00104780/frame.html [serial on the Internet]
33. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 20 1998 Available from: http://www.mrw.interscience.wiley. com/cochrane/clcentral/articles/319/CN-00151319/frame.html [serial on the Internet]
34. P. Sever, B. Dahlof, and N. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 685 696
35. R.H. Knopp, M. d'Emden, J.G. Smilde, and S.J. Pocock Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 7 2006 Available from: http://www.mrw.interscience.wiley.com/cochrane/clcentral/ articles/112/CN-00566112/frame.html [serial on the Internet]
36. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
37. D. Waters, L. Higginson, and P. Gladstone Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial Circulation 3 1994 Available from: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/642/ CN-00099642/frame.html [serial on the Internet]
38. H.P. Bestehorn, U.F. Rensing, and H. Roskamm The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS) Eur Heart J 18 1997 226 234
39. A. Kleemann, S. Eckert, and A. von Eckardstein Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT) Eur Heart J 19 1999 Available from: http://www.mrw.interscience.wiley.com/ cochrane/clcentral/articles/621/CN-00167621/frame.html [serial on the Internet]
40. R.H. Bradford, C.L. Shear, and A.N. Chremos Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia Arch Intern Med 1 1991 Available from: http://www.mrw. interscience.wiley.com/cochrane/clcentral/articles/215/CN-00072215/frame.html [serial on the Internet]
41. P.W. Serruys, D.P. Foley, and G. Jackson A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial Eur Heart J 20 1999 58 69
42. A.H. Liem, A.J. van Boven, and N.J. Veeger Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial Eur Heart J 23 2002 1931 1937
43. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
44. J.C. Patrick, F. Pim, and M. Carlos For the Lescol Intervention Prevention Study (LIPS) investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention JAMA 287 2002 3215 3222
45. G. Riegger, C. Abletshauser, and M. Ludwig The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment Atherosclerosis 144 1999 263 270
46. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) Lancet 344 1994 633 638
47. K.K. Teo, J.R. Burton, and C.E. Buller Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102 2000 1748 1754
48. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised with pravastatin vs usual care JAMA 288 2002 2998 3007
49. M. Mercuri, M.G. Bond, and C.R. Sirtori Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study Am J Med 101 1996 627 634
50. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
51. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico) Ital Heart J 1 2000 810 820
52. S.A. Anderssen, A.K. Hjelstuen, I. Hjermann, K. Bjerkan, and I. Holme Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives Atherosclerosis 2 2005 Available from: http://www.mrw.interscience.wiley.com/ cochrane/clcentral/articles/123/CN-00511123/frame.html [serial on the Internet]
53. R. Salonen, K. Nyyssonen, and E. Porkkala Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries Circulation 92 1995 1758 1764
54. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 339 1998 1349 1357
55. B. Pitt, G.B. Mancini, S.G. Ellis, H.S. Rosman, J.S. Park, and M.E. McGovern Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation J Am Coll Cardiol 26 1995 1133 1139
56. J.R. Crouse III, R.P. Byington, and M.G. Bond Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) Am J Cardiol 75 1995 455 459
57. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients Am J Cardiol 72 1993 1031 1037
58. M.E. Bertrand, E.P. McFadden, and J.C. Fruchart Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT trial investigators. Prevention of restenosis by elisor after transluminal coronary angioplasty J Am Coll Cardiol 30 1997 863 869
59. F.W. Asselbergs, G.F. Diercks, and H.L. Hillege Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 2004 2809 2816
60. J. Shephred, G.J. Blauw, and M.B. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
61. J.W. Jukema, A.V. Bruschke, and A.J. van Boven Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) Circulation 91 1995 2528 2540
62. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
63. B.D. Chiodini, M.G. Franzosi, and S. Barlera Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study Eur Heart J 16 2007 Available from: http://www.mrw.interscience.wiley.com/cochrane/ clcentral/articles/361/CN-00627361/frame.html [serial on the Internet]
64. F.M. Sacks, M.A. Pfeffer, and L. Moye Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) Am J Cardiol 68 1991 1436 1446
65. P.M. Ridker, F.A. Fonseca, and J. Genest Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein Am J Cardiol 11 2007 Available from: http://www.mrw.interscience.wiley.com/cochrane/ clcentral/articles/260/CN-00621260/frame.html [serial on the Internet].
66. M. de Lorgeril, P. Salen, and J. Abramson Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal Arch Intern Med 170 2010 1032 1036
67. S. Kaul, R.P. Morrissey, and G.A. Diamond By Jove! What is a clinician to make of JUPITER? Arch Intern Med 170 2010 1073 1077
68. S.C. Smith Jr., J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute J Am Coll Cardiol 47 2006 2130 2139
69. R. Ara, A. Pandor, J. Stevens, A. Rees, and R. Rafia Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation Health Technol Assess 13 1-74 2009 5 118
70. K. Josan, S.R. Majumdar, and F.A. McAlister The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials CMAJ 178 2008 576 584
71. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
72. T.A. Furukawa, N. Watanabe, I.M. Omori, V.M. Montori, and G.H. Guyatt Association between unreported outcomes and effect size estimates in Cochrane meta-analyses JAMA 297 2007 468 470
73. A.W. Chan, A. Hrobjartsson, M.T. Haahr, P.C. Gotzsche, and D.G. Altman Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles JAMA 291 2004 2457 2465